Polpharma is lined up to copy 3 of the blockbuster drugs on this tracker, which earned $19.6B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Polpharma's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entyvio PB016 |
Takeda | Biosimilar | 2032 | Filed with the FDA Jul 2026; in litigation, sued Aug 2026. FDA accepted the filing in Jul 2026 | ≈$6.0B |
| Ocrevus PB018 |
Roche | Biosimilar | 2029 | Early development. Phase 1 planned for Oct 2026 | ≈$8.4B |
| Tremfya PB019 |
Johnson & Johnson | Biosimilar | 2031 | Early development | $5.2B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Polpharma's share of it.
Polpharma has applications filed for Entyvio; and copies in development for Ocrevus and Tremfya. It has is in court over 1. Of the 70 makers we follow, 25 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.